Pharmaceuticals News and Research

RSS

Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Rich Pharmaceuticals, Inc. is pleased to announce that the Company has received approval from the U.S. Food and Drug Administration to commence its Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients.

28 Dec 2015

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

A new study by researchers from Harvard T.H. Chan School of Public Health and colleagues describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.

24 Dec 2015

Selexipag holds promise for treatment of pulmonary hypertension

Living with pulmonary arterial hypertension is challenging, but the chore of treating the rare heart disease may change following promising clinical trial data to be published in the Dec. 24 issue of the New England Journal of Medicine.

24 Dec 2015

Simplified mathematical model to study spread of dengue fever in urban areas

Mathematics is often implemented in healthcare and medical research. From health management to the bio-pharmaceutical fields, math modeling can be used to predict the spread of diseases, how to prevent epidemics and so much more.

24 Dec 2015

China leads in pharma sector patent filings among BRIC Nations

With growth rates in developed markets sliding downwards, emerging markets with higher growth rates such as BRIC are expected to be the key drivers of revenue growth for multinational pharma companies. Therefore, multinational pharmaceutical corporations should have a well-planned strategy for each of the BRIC members in order to achieve global prominence.

24 Dec 2015

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.

24 Dec 2015

EMA CHMP considers AcelRx's ARX-04 for acute pain treatment for centralized review

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the intended treatment of acute pain, reported that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has confirmed that a Marketing Authorization Application (MAA) for ARX-04 may be submitted in the European Union (EU) under the Agency's centralized procedure.

24 Dec 2015

Medication poisoning threatens young children in poor areas

Children younger than 5 who live in economically disadvantaged areas had a greater risk of medication poisoning that resulted in referral to a health care facility, according to scientists at the University of Pittsburgh Graduate School of Public Health and the University of California, San Diego. These areas were rural and experienced high unemployment, along with lower rates of high school graduation and lower household income.

23 Dec 2015

Researchers, patients trade new insights at International Dementia with Lewy Bodies Conference

You thought Alzheimer's was complicated? Or Parkinson's? Try dementia with Lewy bodies, the disease occupying the awkward territory between those two poles.

23 Dec 2015

Cardiome files NDS with Health Canada's TPD for approval of intravenous vernakalant

Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the filing of a New Drug Submission (NDS) with Health Canada's Therapeutic Products Directorate (TPD) seeking Canadian approval of intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults with AF for up to 7 days.

23 Dec 2015

Alexza receives notification letter regarding noncompliance with NASDAQ listing rule

Alexza Pharmaceuticals, Inc. announced today that on December 17, 2015, the Company received a letter from the Nasdaq Staff indicating that the Company had not regained compliance with the $35 million market capitalization requirement for continued listing on The Nasdaq Capital Market by the end of the previously granted compliance period, which expired on December 16, 2015.

23 Dec 2015

Novel drug shows promise in mouse models of human metastatic breast cancer

A doctor treating a patient with a potentially fatal metastatic breast tumor would be very pleased to find, after administering a round of treatment, that the primary tumor had undergone a change in character - from aggressive to static, and no longer shedding cells that can colonize distant organs of the body. Indeed, most patients with breast and other forms of cancer who succumb to the illness do so because of the cancer's unstoppable spread.

23 Dec 2015

Zurampic (lesinurad) approved to treat high levels of hyperuricemia associated with gout

The U.S. Food and Drug Administration today approved Zurampic (lesinurad) to treat high levels of uric acid in the blood (hyperuricemia) associated with gout, when used in combination with a xanthine oxidase inhibitor (XOI), a type of drug approved to reduce the production of uric acid in the body.

22 Dec 2015

HBI-8000 granted orphan drug designation in Japan for treatment of peripheral T-cell lymphoma

HUYA Bioscience International, Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL).

22 Dec 2015

FDA approves Uptravi tablets to treat adults with pulmonary arterial hypertension

On December 21, the U.S. Food and Drug Administration approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation.

22 Dec 2015

Vertice Pharma closes previously announced acquisition of VistaPharm

Vertice Pharma, a specialty pharmaceuticals company focused on improving patients' health, today announced it closed on the previously announced acquisition of VistaPharm, a specialized generics manufacturer of liquid and unit dosage pain medications for the hospital market, retail pharmacy and outpatient clinics. Terms of the transaction were not disclosed.

22 Dec 2015

Bern study sheds light on the brain mechanism of arousal

Scientists from Bern have discovered a mechanism which is responsible for the rapid arousal from sleep and anesthesia in the brain. The results of their study suggest new strategies for the medical treatment of sleep disorders and recovery of consciousness in vegetative states.

22 Dec 2015

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].

22 Dec 2015

CSL submits rIX-FP new drug application to Japan's Pharmaceuticals and Medical Devices Agency

Global biotherapeutics leader CSL Behring announced today that the company has submitted its new drug application to Japan's Pharmaceuticals and Medical Devices Agency for its investigational fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).

22 Dec 2015

New drug approved by FDA for treatment of von Willebrand disease

"VONVENDI [von Willebrand factor (Recombinant)]", the new drug from Baxalta Incorporated, a global biopharmaceutical company recently spun off from Baxter International, has just been approved by the United States Food and Drug Administration.

22 Dec 2015

Pharmaceuticals News and Research

Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

Selexipag holds promise for treatment of pulmonary hypertension

Simplified mathematical model to study spread of dengue fever in urban areas

China leads in pharma sector patent filings among BRIC Nations

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

EMA CHMP considers AcelRx's ARX-04 for acute pain treatment for centralized review

Medication poisoning threatens young children in poor areas

Researchers, patients trade new insights at International Dementia with Lewy Bodies Conference

Cardiome files NDS with Health Canada's TPD for approval of intravenous vernakalant

Alexza receives notification letter regarding noncompliance with NASDAQ listing rule

Novel drug shows promise in mouse models of human metastatic breast cancer

Zurampic (lesinurad) approved to treat high levels of hyperuricemia associated with gout

HBI-8000 granted orphan drug designation in Japan for treatment of peripheral T-cell lymphoma

FDA approves Uptravi tablets to treat adults with pulmonary arterial hypertension

Vertice Pharma closes previously announced acquisition of VistaPharm

Bern study sheds light on the brain mechanism of arousal

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

CSL submits rIX-FP new drug application to Japan's Pharmaceuticals and Medical Devices Agency

New drug approved by FDA for treatment of von Willebrand disease

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring